Global Dendritic Cell and Tumor Cell Vaccines Market Restraints
Withdrawal of dendritic cell and tumor cell vaccines from its clinical trials are expected to hamper the global dendritic cell and tumor cell vaccines clinical progress. For instance, in March 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, conducted its clinical trial for dendritic cell vaccine with radiotherapy. It was being studied for the treatment of renal cancer. However, it got withdrawn in its second phase of clinical trial (reason unspecified). Hence, this factor may have a negative impact on the global dendritic and tumor cell vaccine market growth.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients